Open-label, phase 2 study to evaluate the efficacy and safety of CUDC-907 in patients with relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC alterations (#668)
Laufzeit: 01.01.2017 - 31.12.2017
imported
Kurzfassung
This clinical trial tests the efficacy of a new therapy for relapsed/refractory MYC-altered diffuse large B-cell lymphoma.
